Serum Antibody Against NY-ESO-1 and XAGE1 Antigens Potentially Predicts Clinical Responses to Anti–PD-1 Therapy in NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Thoracic Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Serum Antibody Against NY-ESO-1 and XAGE1 Antigens Potentially Predicts Clinical Responses to Anti-Programmed Cell Death-1 Therapy in NSCLC
J Thorac Oncol 2019 Dec 01;14(12)2071-2083, Y Ohue, K Kurose, T Karasaki, M Isobe, T Yamaoka, J Futami, I Irei, T Masuda, M Fukuda, A Kinoshita, H Matsushita, K Shimizu, M Nakata, N Hattori, H Yamaguchi, M Fukuda, R Nozawa, K Kakimi, M OkaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.